Get the Stockscreener App
3.29
0.45%
-0.015
Neuroone Medical Technologies Corp stock is traded at $3.29, with a volume of 47,033.
It is down -0.45% in the last 24 hours and down -27.37% over the past month.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
See More
Previous Close:
$3.305
Open:
$3.34
24h Volume:
47,033
Relative Volume:
1.29
Market Cap:
$28.63M
Revenue:
$9.72M
Net Income/Loss:
$-6.64M
P/E Ratio:
-4.129
EPS:
-0.7968
Net Cash Flow:
$-7.57M
1W Performance:
+1.54%
1M Performance:
-27.37%
6M Performance:
-23.43%
1Y Performance:
-20.25%
1-Day Range:
$3.15
$3.34
1-Week Range:
$3.11
$3.465
52-Week Range:
$3.11
$6.96
Neuroone Medical Technologies Corp Stock (NMTC) Company Profile
Name
Neuroone Medical Technologies Corp
Sector
Industry
Phone
(952) 426-1383
Address
7599 ANAGRAM DR, EDEN PRAIRIE
Compare NMTC vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.99 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.38 | 3.16B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.54 | 425.01M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.909 | 269.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.61 | 0 | 0 | 0 | 0 | 0.00 |
Neuroone Medical Technologies Corp Stock (NMTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-29-22 | Downgrade | Craig Hallum | Buy → Hold |
Neuroone Medical Technologies Corp Stock (NMTC) Latest News
NeuroOne Medical Technologies Corp (NMTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NeuroOne Medical Technologies Corp - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
NeuroOne Medical Technologies 10-Q/A Restatement for Q2 2026 – Financial Statement Corrections and Impact - Minichart
NeuroOne Medical Technologies Corporation Files Form 8-K Current Report with NASDAQ Listing Information - Minichart
NeuroOne Medical Technologies updates at-the-market offering for up to $13.4 million - Investing.com
NeuroOne to sell up to $13.4M in common stock through updated ATM prospectus - TradingView
NeuroOne (NASDAQ: NMTC) ups at‑the‑market capacity to $13.4M via JonesTrading - Stock Titan
NeuroOne Medical Technologies (NMTC) refreshes $13.4M at-the-market share offering - Stock Titan
NeuroOne Medical (NASDAQ: NMTC) restates revenue and warns on going concern - Stock Titan
NMTC Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Costs PersistGeographic Revenue Trends - newsline.com
NeuroOne (NMTC) Q2 2026 Earnings Transcript - AOL.com
NMTCNeuroOne Medical Technologies Corporation stock news, filings & ratings - Quantisnow
NeuroOne Medical | 4: Statement of changes in beneficial ownership of securities-Officer Christianson Mark - Moomoo
NeuroOne Medical Technologies to Restate Q1 2026 Financials After Revenue Overstatement; Reaffirms $10.5M FY2026 Guidance - Minichart
According to documents submitted by NEUROONE MEDICAL TECH to the U.S. Securities and Exchange Commission, the company has restated its financial data for the first quarter of 2026 to correct a previous overstatement of revenue by approximately $50 - Bitget
NeuroOne(R) Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026 - Scott Coop
NeuroOne (Nasdaq: NMTC) to restate March 31 2026 results, keeps guidance - Stock Titan
Earnings call transcript: NeuroOne misses Q2 2026 forecasts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: NeuroOne misses Q2 2026 forecasts, stock rises - Investing.com
Minne InnoNeuroOne CEO Dave Rosa talks uplisting on Nasdaq, year ahead - The Business Journals
Maxim Group Maintains NeuroOne Medical(NMTC.US) With Buy Rating, Maintains Target Price $13 - Moomoo
NMTC Maintains Buy Rating by Ladenburg Thalmann -- Price Target Raised to $8.80 - GuruFocus
NeuroOne Medical Tech Price Target Raised to $8.00/Share From $1.60 by Ladenburg Thalmann - Moomoo
NeuroOne Medical Tech Q2 2026 Earnings Call Transcript - Sahm
NeuroOne Medical (NMTC) Price Target Raised to $8 - GuruFocus
Ladenburg Thalmann Maintains NeuroOne Medical(NMTC.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
NeuroOne Medical Technologies Corp 2026 Q2 Financial Report: Revenue, Product Updates, and Financial Statements - Minichart
NeuroOne Medical Technologies Corp (NMTC) Q2 2026 Earnings Call - GuruFocus
Q2 2026 NeuroOne Medical Technologies Corp Earnings Call Transcript - GuruFocus
Earnings call transcript: NeuroOne misses Q2 2026 forecasts, stock dips - Investing.com India
Is NeuroOne Medical Technologies (NMTC) 42.2% Undervalued or a P - GuruFocus
Earnings call transcript: NeuroOne misses Q2 2026 forecasts, stock dips By Investing.com - Investing.com Canada
NEUROONE MEDICAL TECHNOLOGIES Corp 2Q 2026: Revenue $2.39M, EPS ($0.25) — 10-Q Summary - TradingView
NeuroOne Medical | 10-Q: Q2 2026 Earnings Report - Moomoo
NeuroOne (NASDAQ: NMTC) grows sales but warns on going concern - Stock Titan
NeuroOne posts Q2 fiscal 2026: Product revenue $2.4M, net loss $2.1M - TradingView
NeuroOne (Nasdaq: NMTC) Q2 revenue jumps 72% while net loss persists - Stock Titan
EQS-News: NeuroOne Medical Technologies: NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update - FinanzNachrichten.de
NeuroOne Medical Technologies Corp (NMTC) Q2 2026 Earnings Repor - GuruFocus
NeuroOne Medical | 8-K: Current report - Moomoo
NeuroOne Medical Technologies Corp expected to post a loss of 23 cents a shareEarnings Preview - TradingView
NeuroOne Medical Technologies Corporation Receives Nasdaq Deficiency Notice for Minimum Bid Price Compliance – 8-K Filing April 30, 2026 - Minichart
NeuroOne (NASDAQ: NMTC) restores compliance with Nasdaq $1.00 bid rule - Stock Titan
NeuroOne Medical Technologies Announces CFO Transition and Release Agreement Filing - Minichart
EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Announces Chief Financial Officer Succession Plan - FinanzNachrichten.de
CFO transition at NeuroOne (NASDAQ: NMTC) as Volker steps up - Stock Titan
NMTC Price Today: NeuroOne Medical Technologies Corporation Stock Price, Quote & Chart | MEXC - MEXC Exchange
NeuroOne(R) to Report Second Quarter Fiscal Year 2026 Financial Results on Tuesday, May 12 at 8:30 a.m. Eastern Time - Yahoo Finance
Neuroone Medical Technologies Corp Stock (NMTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):